JEFFREY P. CALLEN, M.D.; JOSEPH J. CHANDA, M.D.; MAREK A. STAWISKI, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: In "Dermatomyositis and Malignancy" (Ann Intern Med 84:68-76, 1976), Barnes has thoroughly reviewed the pertinent literature. She concludes from this review that the incidence of malignancy in dermatomyositis is increased; the tumors associated with dermatomyositis are overrepresented by ovarian and stomach cancers and underrepresented by colorectal cancers; and in some cases tumor therapy, steroids, or immunosuppressives may lead to improvement in the myopathy. We have reservations about these conclusions for these reasons. First, the literature reviewed contains many case reports and series in which the diagnosis of dermatomyositis has not been established on the basis of specific
JEFFREY P. CALLEN, JOSEPH J. CHANDA, MAREK A. STAWISKI. Dermatomyositis and Malignancy. Ann Intern Med. 1976;84:751–752. doi: 10.7326/0003-4819-84-6-751_2
Download citation file:
Published: Ann Intern Med. 1976;84(6):751-752.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use